Combined Modality Management of Sinonasal Anaplastic Lymphoma Kinase Negative Anaplastic Large Cell Lymphoma in a Geriatric Patient-Report of a Rare Case.

Head and neck pathology Pub Date : 2021-12-01 Epub Date: 2021-01-04 DOI:10.1007/s12105-020-01276-3
Ahitagni Biswas, Sorun Shishak, Swarnaditya Roy, Aanchal Kakkar
{"title":"Combined Modality Management of Sinonasal Anaplastic Lymphoma Kinase Negative Anaplastic Large Cell Lymphoma in a Geriatric Patient-Report of a Rare Case.","authors":"Ahitagni Biswas,&nbsp;Sorun Shishak,&nbsp;Swarnaditya Roy,&nbsp;Aanchal Kakkar","doi":"10.1007/s12105-020-01276-3","DOIUrl":null,"url":null,"abstract":"<p><p>Sinonasal anaplastic lymphoma kinase(ALK)-negative anaplastic large cell lymphoma(ALCL) without nodal involvement is exceedingly rare and the rarity of this tumor often engenders diagnostic dilemma. It has been mostly reported in pediatric, adolescent and young adult patients, mostly of Asian origin. A 70-year-old female patient presented with a mass in the left nasal cavity causing nasal obstruction for 5 months. On clinical and radiological examination, there was a 5.7 cm mass in the left nasal cavity, completely obliterating the left ethmoid sinus. Biopsy from the nasal mass showed a poorly differentiated malignant tumour with large cells arranged in sheets. On immunohistochemistry, the tumour cells were positive for leukocyte common antigen(LCA), CD30, CD43, BCL6 and focally for CD5, TIA1, granzyme B and epithelial membrane antigen(EMA), and were negative for CD56, EBV-LMP1, CD79a, PAX5, myeloperoxidase, CD34, CD7, CD4, CD8, CD138, ALK and p63, suggestive of ALK-negative ALCL. Rest of the lymphoma work-up was essentially normal and she had stage IE disease. She was treated with prephase chemotherapy (Vincristine and Prednisolone) followed by 4 cycles of CEOP[Cyclophosphamide, Etoposide (from 2nd cycle onwards), Vincristine and Prednisolone] regimen and local radiotherapy (36 Gy/20 fractions/4 weeks) by intensity modulated radiotherapy(IMRT) technique resulting in complete clinical and radiological response. At last follow-up visit, 15 months from the initial diagnosis, she was alive and disease free. Sinonasal ALK-negative ALCL is a rare tumor which can be effectively treated with a combination of multi-agent CHOP/CHOP-like regimen and local conformal radiotherapy in geriatric patients.</p>","PeriodicalId":520636,"journal":{"name":"Head and neck pathology","volume":" ","pages":"1335-1344"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12105-020-01276-3","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Head and neck pathology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12105-020-01276-3","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/4 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Sinonasal anaplastic lymphoma kinase(ALK)-negative anaplastic large cell lymphoma(ALCL) without nodal involvement is exceedingly rare and the rarity of this tumor often engenders diagnostic dilemma. It has been mostly reported in pediatric, adolescent and young adult patients, mostly of Asian origin. A 70-year-old female patient presented with a mass in the left nasal cavity causing nasal obstruction for 5 months. On clinical and radiological examination, there was a 5.7 cm mass in the left nasal cavity, completely obliterating the left ethmoid sinus. Biopsy from the nasal mass showed a poorly differentiated malignant tumour with large cells arranged in sheets. On immunohistochemistry, the tumour cells were positive for leukocyte common antigen(LCA), CD30, CD43, BCL6 and focally for CD5, TIA1, granzyme B and epithelial membrane antigen(EMA), and were negative for CD56, EBV-LMP1, CD79a, PAX5, myeloperoxidase, CD34, CD7, CD4, CD8, CD138, ALK and p63, suggestive of ALK-negative ALCL. Rest of the lymphoma work-up was essentially normal and she had stage IE disease. She was treated with prephase chemotherapy (Vincristine and Prednisolone) followed by 4 cycles of CEOP[Cyclophosphamide, Etoposide (from 2nd cycle onwards), Vincristine and Prednisolone] regimen and local radiotherapy (36 Gy/20 fractions/4 weeks) by intensity modulated radiotherapy(IMRT) technique resulting in complete clinical and radiological response. At last follow-up visit, 15 months from the initial diagnosis, she was alive and disease free. Sinonasal ALK-negative ALCL is a rare tumor which can be effectively treated with a combination of multi-agent CHOP/CHOP-like regimen and local conformal radiotherapy in geriatric patients.

Abstract Image

Abstract Image

联合治疗鼻窦间变性淋巴瘤激酶阴性的老年间变性大细胞淋巴瘤1例报道。
无淋巴结累及的鼻窦间变性淋巴瘤激酶(ALK)阴性间变性大细胞淋巴瘤(ALCL)极为罕见,这种肿瘤的罕见性常常导致诊断困境。据报道,它主要发生在儿童、青少年和年轻成人患者中,主要是亚裔。一位70岁的女性患者表现为左鼻腔肿块导致鼻塞5个月。经临床及影像学检查,左侧鼻腔内有5.7 cm肿块,完全阻塞左侧筛窦。鼻肿块活检显示为低分化恶性肿瘤,大细胞呈片状排列。免疫组化结果显示,肿瘤细胞白细胞共同抗原(LCA)、CD30、CD43、BCL6阳性,局部CD5、TIA1、颗粒酶B和上皮膜抗原(EMA)阳性,CD56、EBV-LMP1、CD79a、PAX5、髓过氧化物酶、CD34、CD7、CD4、CD8、CD138、ALK和p63阴性,提示ALK阴性。其余的淋巴瘤检查基本正常,她患有IE期疾病。患者接受前期化疗(长春新碱和强的松龙),随后进行4个周期的CEOP[环磷酰胺、依托泊苷(从第2周期开始)、长春新碱和强的松龙]方案,并通过强度调节放疗(IMRT)技术进行局部放疗(36 Gy/20次/4周),临床和放射学反应完全。在最后一次随访中,从最初诊断15个月后,她还活着,没有疾病。鼻窦alk阴性ALCL是一种罕见的肿瘤,多药CHOP/CHOP样方案联合局部适形放疗可有效治疗老年患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信